Genes may determine success of anti-inflammatory therapy for rheumatoid arthritisJune 14, 2001Small genetic differences may explain why the same drug works well in one individual but not in another. These genetic variations could be exploited to develop individually tailored treatment programmes for rheumatoid arthritis, Swedish researchers said today. Speaking at the Press Conference during EULAR 2001, the prestigious annual congress of the European League Against Rheumatism (EULAR), Dr Leonid Padyukov, of the Karolinska Hospital in Stockholm, presented new data from a study of 123 patients with active rheumatoid arthritis (RA). The study focused on genetic differences that influence the activity of tumour necrosis factor (TNF), a molecule that plays a pivotal role in the progression of RA. TNF is a pro-inflammatory cytokine, a protein that once activated, stimulates other immune cells to attack the joints and surrounding tissues. Drugs that block TNF activity are now in use for the treatment of this potentially crippling disease. "We know that the regulation of cytokine production at the genetic level can involve several different genetic variations or polymorphisms in control regions in DNA. We also know that different patients with RA respond differently to anti-TNF therapy. Our study set out to see if this difference in response to treatment may be due partly to the patient's individual genetic polymorphisms," explained Dr Padyukov. Patients were treated with the TNF-blocking therapy etanercept, a soluble TNF receptor that ties up circulating TNF and down-regulates the inflammation in RA patients. These patients were then grouped according to whether or not they responded to treatment. The researchers analysed DNA from the patients and found that certain genetic polymorphisms were associated with response to treatment. "We found distinct polymorphisms in genes for TNF and interleukin 10 (IL-10). Patients with a certain type of both the TNF and IL-10 polymorphism, -308 TNFA and -1082 IL-10, were most likely to respond to treatment," said Dr Padyukov. Commenting on the importance and clinical relevance of these findings, Dr Padyukov concluded by saying: "The potential of using genetic markers to identify patients with RA who might most benefit from anti-TNF drugs is a very attractive development. It could help rheumatologists to optimise patient treatment and make the most of available resources. With the publication of the human genome map and sequence this year, we are likely to see significant advances in this growing field of tailoring and individualisation of therapy." Gardiner-Caldwell Communications Ltd |
|||||||||||||||||||||
| Related Arthritis Current Events and Arthritis News Articles Too much physical activity may lead to arthritis Middle-aged men and women who engage in high levels of physical activity may be unknowingly causing damage to their knees and increasing their risk for osteoarthritis, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA). Multiple health concerns surface as winter, vitamin D deficiences arrive A string of recent discoveries about the multiple health benefits of vitamin D has renewed interest in this multi-purpose nutrient, increased awareness of the huge numbers of people who are deficient in it, spurred research and even led to an appreciation of it as "nature's antibiotic." Can EP4 agonist alleviate gastric lesions? Over 300 million patients use non-steroidal anti-inflammatory drugs (NSAIDs) in the world to treat pain, arthritis, fever and other diseases. Nearly 30% of the users suffer from gastric lesions and bleeding. Thoughtful words help couples stay fighting fit Couples who bring thoughtful words to a fight release lower amounts of stress-related proteins, suggesting that rational communication between partners can ease the impact of marital conflict on the immune system. Penn Study Provides First Clear Idea of How Rare Bone Disease Progresses An international team of scientists, led by researchers at the University of Pennsylvania School of Medicine, is taking the first step in developing a treatment for a rare genetic disorder called fibrodysplasia ossificans progressiva (FOP), in which the body's skeletal muscles and soft connective tissue turns to bone, immobilizing patients over a lifetime with a second skeleton. Aileron collaborates study in Nature: Stapled peptides inhibit Notch1 transcription factor This research validates the potential for Stapled Peptides to modulate key intracellular biological targets, such as transcription factors, that have not been addressable with current small molecule or biologic drug modalities. Researchers find new way to attack inflammation in Graves' eye disease A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Common Pain Relievers May Dilute Power of Flu Shots With flu vaccination season in full swing, research from the University of Rochester Medical Center cautions that use of many common pain killers - Advil, Tylenol, aspirin - at the time of injection may blunt the effect of the shot and have a negative effect on the immune system. Mending meniscals in children, improving diagnosis and recovery The meniscus is a rubber-like, crescent moon-shaped cartilage cushion that sits between the leg and thigh bone. Each knee has two menisci: one on the inside of the knee joint and one on the outside. Study finds link between childhood physical abuse and arthritis Adults who had experienced physical abuse as children have 56 per cent higher odds of osteoarthritis compared to those who have not been abused, according to a new study by University of Toronto researchers. More Arthritis Current Events and Arthritis News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||